19-Jun-2018 - sanofi-aventis Groupe

Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site

Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.

“Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility” said Thomas Eldered, CEO of Recipharm.

“We are delighted that the Holmes Chapel site is being bought by a company who will further develop the site and its employees, and bring opportunities to utilise the existing technologies and capabilities” said Volker Keuth, Head of Cartridge Division & Emerging Markets, at Sanofi.

The Holmes Chapel manufacturing facility is one of the leading sites of its type in Europe and is home to a team of more than 450 specialist employees. All employees will automatically transfer to Recipharm.

The transaction is expected to close in Q4 2018, after customary licences and permissions have been obtained.

Facts, background information, dossiers
  • Recipharm
  • Sanofi-aventis
  • production plants
More about Sanofi-Aventis
  • News

    Evotec receives € 3 million payment from Sanofi

    Evotec SE announced successful achievement of a third milestone in their diabetes research alliance with Sanofi (“TargetBCD”), resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy progr ... more

    Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse

    Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Evotec has had a successful track record of managing Sanofi’s powder compounds at its Toulouse site since 2015. Under the terms of the new agreement, Sanofi will t ... more

    Sanofi and Google to develop new healthcare Innovation Lab

    Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. “We stand on the forefront of a new age for biology and human health, with t ... more

  • Companies

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    sanofi-aventis Groupe

    One of the world's leading pharmaceutical companies and number 1 in Europe. Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: diabetes, oncology, thrombosis, cardiovascular diseases, central nervous system (CNS) and internal medicine. About 100,000 employees worl ... more

More about Recipharm
  • News

    Recipharm releases first serialised products to Europe

    Recipharm has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden. In 2016 Recipharm committed to invest 40 million euros in preparing its facilities for the European Falsified Medicines Directive (EU FMD). The release of its first ... more

    Recipharm invests in Brexit preparations

    Recipharm has established a dedicated taskforce to manage the potential impact of Brexit on its organisation. With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations an ... more

    Recipharm awarded for growth in France

    Recipharm, a contract development and manufacturing organisation (CDMO), has received recognition for its commitment to its French operations. The award “le Prix d’Excellence 2017 - Spécial Sciences de la vie” is presented by the Swedish Chamber of Commerce in France. The award is to acknow ... more

  • Companies

    Recipharm AB

    Recipharm is a leading contract development and manufacturing organisation based in Europe. The Company operates nine main manufacturing facilities in Sweden, France, the UK and Switzerland and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with in exc ... more